Recipharm appoints new General Manager in Research Triangle Park, USA
Recipharm, the contract development and manufacturing organisation (CDMO), has appointed Ann Flodin as General Manager of its wholly owned new subsidiary Recipharm Laboratories Inc. in Research Triangle Park, North Carolina, USA, formerly Cirrus Pharmaceuticals Inc.
Following the acquisition of Kemwell’s US development business in April 2016, Ann Flodin will be responsible for managing daily operations in Recipharm in Research Triangle Park and will focus on expanding and strengthening the development services Recipharm offers its customers in the US.
With a background in chemical engineering, Ann has more than 20 years’ experience within the pharmaceutical industry, with knowledge of both contract development and manufacturing services. Ann joined Recipharm in 1996 as a scientist within Process Engineering before moving on to manage the pharmaceutical development laboratory. She joins Recipharm in Research Triangle Park from a senior position in Group Operations Development and has previously been General Manager at Recipharm in Höganäs, Sweden.
Commenting on the appointment, Executive Vice President Carl-Johan Spak said: “Ann brings valuable experience to Recipharm in Research Triangle Park having worked within a variety of roles within the Group. She and her team will contribute greatly to the ongoing development of Recipharm and its establishment in the US.”
Recipharm’s operations in Research Triangle Park will enable the CDMO to significantly strengthen the support services it offers to pharmaceutical companies in the US. Recipharm will provide specialist pharmaceutical and analytical development services with a special focus on inhalation, topical and transdermal products. In addition, the organisation will provide US customers with access to a broad range of capabilities and competencies from other parts of the Recipharm Group.
Ann Flodin said: “Having worked with Recipharm for 20 years and enjoyed the spirit and ambition of this fast-growing company, I am excited to now be part of our US endeavor. Our ultimate goal is to ensure Recipharm is the preferred partner for pharmaceutical development services worldwide. I am looking forward to working with the specialists at Research Triangle Park to grow our US platform and create an outstanding development organisation in collaboration with our colleagues in Sweden, Italy, France and Israel.”
Carl-Johan Spak, Executive Vice President Global Technologies, email@example.com, + 46 708 840 154.
For media enquiries, please contact Lindsay Baldry at ramarketing: firstname.lastname@example.org, + 44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 3,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.0 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03